SFM
TVTX icon

Sphera Funds Management’s Travere Therapeutics TVTX Stock Holding History

Sphera Funds Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-335,333
Closed -$6.3M – 137
2025
Q2 		$4.96M Buy
335,333
+135,333
+68% +$2.24M 1.16% 28
2025
Q1 		$3.58M Sell
200,000
-20,700
-9% -$420K 0.83% 35
2024
Q4 		$3.84M Buy
+220,700
New +$3.9M 0.7% 54
2023
Q3 		– Sell
-213,462
Closed -$3.28M – 103
2023
Q2 		$3.28M Buy
213,462
+25,962
+14% +$472K 0.51% 62
2023
Q1 		$4.22M Buy
+187,500
New +$3.99M 0.7% 49
2020
Q3 		– Sell
-250,000
Closed -$5.1M – 114
2020
Q2 		$5.1M Buy
+250,000
New +$3.98M 0.48% 51
2020
Q1 		– Sell
-317,381
Closed -$4.51M – 98
2019
Q4 		$4.51M Sell
317,381
-12,822
-4% -$164K 0.37% 60
2019
Q3 		$3.83M Sell
330,203
-200,475
-38% -$3.31M 0.59% 53
2019
Q2 		$10.7M Buy
530,678
+95,000
+22% +$1.88M 1.46% 16
2019
Q1 		$9.86M Buy
435,678
+110,000
+34% +$2.43M 0.9% 20
2018
Q4 		$7.37M Hold
325,678
– – 0.83% 30
2018
Q3 		$9.36M Sell
325,678
-27,394
-8% -$783K 1.07% 21
2018
Q2 		$9.63M Buy
353,072
+133,072
+60% +$3.54M 1.33% 19
2018
Q1 		$4.92M Buy
+220,000
New +$5.24M 0.75% 42
2017
Q4 		– Sell
-174,131
Closed -$4.33M – 151
2017
Q3 		$4.33M Sell
174,131
-35,000
-17% -$771K 0.62% 44
2017
Q2 		$4.05M Hold
209,131
– – 0.69% 43
2017
Q1 		$3.86M Buy
209,131
+65,157
+45% +$1.27M 0.75% 35
2016
Q4 		$2.73M Sell
143,974
-46,026
-24% -$941K 0.69% 41
2016
Q3 		$4.25M Buy
190,000
+40,000
+27% +$761K 0.69% 33
2016
Q2 		$2.67M Buy
+150,000
New +$2.43M 0.69% 45
2016
Q1 		– Sell
-135,000
Closed -$2.6M – 118
2015
Q4 		$2.6M Sell
135,000
-15,000
-10% -$300K 0.38% 67
2015
Q3 		$3.04M Buy
+150,000
New +$4.44M 0.39% 59
2015
Q2 		– Sell
-111,392
Closed -$2.67M – 156
2015
Q1 		$2.67M Buy
+111,392
New +$1.7M 0.28% 91

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sphera Funds Management's TVTX Position: Q3 2025 in Review

Sphera Funds Management sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 335,333 shares — an estimated $6.3M sold.

Sphera Funds Management first reported a position in TVTX in Q1 2015 and held it in 23 quarters. The position peaked at $10.7M in Q2 2019. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Sphera Funds Management reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sphera Funds Management sold 335,333 Travere Therapeutics shares in Q3 2025, an estimated $6.3M.
  • Sphera Funds Management first reported a position in Travere Therapeutics in Q1 2015 and held it in 23 quarters.
  • Sphera Funds Management's Travere Therapeutics position peaked at $10.7M in Q2 2019.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.